Clinical Trial Update: Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating sequential immunization with a recombinant CHO cell COVID-19 vaccine (NVSI-06-08) followed by an inactivated COVID-19 vacc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infections

Drugs mentioned

• NVSI-06-08 (recombinant COVID-19 vaccine (CHO cells))
• inactivated COVID-19 vaccine (Vero cells)

Snippet

Sponsor: National Vaccine and Serum Institute, China | Conditions: COVID-19 Pneumonia, Coronavirus Infections | Phase 1, Phase 2 | Status: UNKNOWN